TransMedics (TMDX) Group announced that the U.S. FDA has granted full approval of its Investigational Device Exemption for the Next-Generation OCS ENHANCE Heart trial. This follows full FDA approval of the company’s Next-Generation OCS DENOVO Lung IDE trial in January 2026 and conditional IDE approval for the ENHANCE Heart trial in August 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics management to meet virtually with Seaport Research
- TransMedics Group Names New Commercial Leader
- TransMedics selloff on competitor clearance unwarranted, says TD Cowen
- TransMedics falls after FDA clears competitor liver transplant device
- TransMedics Group: Buy Rating Reaffirmed on Durable Growth, OCS Platform Uptake, and Emerging Clinical and Geographic Catalysts